GLP-1a: Going beyond Traditional Use
Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The obj...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2022-01, Vol.23 (2), p.739 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 739 |
| container_title | International journal of molecular sciences |
| container_volume | 23 |
| creator | Laurindo, Lucas Fornari Barbalho, Sandra Maria Guiguer, Elen Landgraf da Silva Soares de Souza, Maricelma de Souza, Gabriela Achete Fidalgo, Thiago Marques Araújo, Adriano Cressoni de Souza Gonzaga, Heron F de Bortoli Teixeira, Daniel de Oliveira Silva Ullmann, Thais Sloan, Katia Portero Sloan, Lance Alan |
| description | Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The objective of this study was to perform a systematic review on the use of GLP-1 other than in treating diabetes. PubMed, Cochrane, and Embase were searched, and the PRISMA guidelines were followed. Nineteen clinical studies were selected. The results showed that GLP-1 agonists can benefit defined off-medication motor scores in Parkinson's Disease and improve emotional well-being. In Alzheimer's disease, GLP-1 analogs can improve the brain's glucose metabolism by improving glucose transport across the blood-brain barrier. In depression, the analogs can improve quality of life and depression scales. GLP-1 analogs can also have a role in treating chemical dependency, inhibiting dopaminergic release in the brain's reward centers, decreasing withdrawal effects and relapses. These medications can also improve lipotoxicity by reducing visceral adiposity and decreasing liver fat deposition, reducing insulin resistance and the development of non-alcoholic fatty liver diseases. The adverse effects are primarily gastrointestinal. Therefore, GLP-1 analogs can benefit other conditions besides traditional diabetes and obesity uses. |
| doi_str_mv | 10.3390/ijms23020739 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8775408</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2622274054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-cd7ea3196fd5d88be70b2c50e3e5f5697f867f3fec493470c551831eeb2a79b83</originalsourceid><addsrcrecordid>eNpdkE1Lw0AQhhdRbK3ePEtADx6M7mc260GQolUo6KE9L5vNpG5JszWbCP33praW6mkG5uFl3gehc4JvGVP4zs0XgTJMsWTqAPUJpzTGOJGHe3sPnYQwx5gyKtQx6jGBBVeU99HVaPweE3MfjbyrZlEGK1_l0aQ2uWucr0wZTQOcoqPClAHOtnOAps9Pk-FLPH4bvQ4fx7HlhDaxzSUYRlRS5CJP0wwkzqgVGBiIQiRKFmkiC1aA5Ypxia0QJGUEIKNGqixlA_SwyV222QJyC1VTm1Iva7cw9Up74_TfS-U-9Mx_6VRKwfE64HobUPvPFkKjFy5YKEtTgW-DpgmlVPKufIde_kPnvq27wj8UYTRhfE3dbChb-xBqKHbPEKzX-vW-_g6_2C-wg399s2_F5H6R</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2621326344</pqid></control><display><type>article</type><title>GLP-1a: Going beyond Traditional Use</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Laurindo, Lucas Fornari ; Barbalho, Sandra Maria ; Guiguer, Elen Landgraf ; da Silva Soares de Souza, Maricelma ; de Souza, Gabriela Achete ; Fidalgo, Thiago Marques ; Araújo, Adriano Cressoni ; de Souza Gonzaga, Heron F ; de Bortoli Teixeira, Daniel ; de Oliveira Silva Ullmann, Thais ; Sloan, Katia Portero ; Sloan, Lance Alan</creator><creatorcontrib>Laurindo, Lucas Fornari ; Barbalho, Sandra Maria ; Guiguer, Elen Landgraf ; da Silva Soares de Souza, Maricelma ; de Souza, Gabriela Achete ; Fidalgo, Thiago Marques ; Araújo, Adriano Cressoni ; de Souza Gonzaga, Heron F ; de Bortoli Teixeira, Daniel ; de Oliveira Silva Ullmann, Thais ; Sloan, Katia Portero ; Sloan, Lance Alan</creatorcontrib><description>Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The objective of this study was to perform a systematic review on the use of GLP-1 other than in treating diabetes. PubMed, Cochrane, and Embase were searched, and the PRISMA guidelines were followed. Nineteen clinical studies were selected. The results showed that GLP-1 agonists can benefit defined off-medication motor scores in Parkinson's Disease and improve emotional well-being. In Alzheimer's disease, GLP-1 analogs can improve the brain's glucose metabolism by improving glucose transport across the blood-brain barrier. In depression, the analogs can improve quality of life and depression scales. GLP-1 analogs can also have a role in treating chemical dependency, inhibiting dopaminergic release in the brain's reward centers, decreasing withdrawal effects and relapses. These medications can also improve lipotoxicity by reducing visceral adiposity and decreasing liver fat deposition, reducing insulin resistance and the development of non-alcoholic fatty liver diseases. The adverse effects are primarily gastrointestinal. Therefore, GLP-1 analogs can benefit other conditions besides traditional diabetes and obesity uses.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms23020739</identifier><identifier>PMID: 35054924</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adipocytes ; Adipose tissue ; Agonists ; Alzheimer's disease ; Analogs ; Apoptosis ; Appetite ; Blood-brain barrier ; Body fat ; Body mass index ; Clinical medicine ; Clinical trials ; Clinical Trials as Topic ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - drug therapy ; Disease Management ; Dopamine receptors ; Drug dosages ; Enzymes ; Fatty liver ; Gastrointestinal system ; Gastrointestinal tract ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Glucagon-Like Peptide 1 - metabolism ; Glucagon-Like Peptide 1 - pharmacology ; Glucagon-Like Peptide 1 - therapeutic use ; Glucagon-Like Peptide-1 Receptor - agonists ; Glucose ; Glucose metabolism ; Glucose transport ; Hepatocytes ; Homeostasis ; Humans ; Hyperglycemia ; Inhibition (psychology) ; Insulin ; Insulin resistance ; Liver ; Liver diseases ; Metabolism ; Neurodegenerative Diseases - drug therapy ; Obesity ; Obesity - drug therapy ; Pancreas ; Parkinson's disease ; Peptide Fragments - metabolism ; Peptide Fragments - pharmacology ; Peptide Fragments - therapeutic use ; Psoriasis ; Quality of life ; Reinforcement ; Review ; Systematic review ; Treatment Outcome ; Weight control ; Well being</subject><ispartof>International journal of molecular sciences, 2022-01, Vol.23 (2), p.739</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-cd7ea3196fd5d88be70b2c50e3e5f5697f867f3fec493470c551831eeb2a79b83</citedby><cites>FETCH-LOGICAL-c412t-cd7ea3196fd5d88be70b2c50e3e5f5697f867f3fec493470c551831eeb2a79b83</cites><orcidid>0000-0002-5716-2444 ; 0000-0002-9930-9694 ; 0000-0003-3159-0982 ; 0000-0002-5035-876X ; 0000-0001-8776-561X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775408/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775408/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35054924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laurindo, Lucas Fornari</creatorcontrib><creatorcontrib>Barbalho, Sandra Maria</creatorcontrib><creatorcontrib>Guiguer, Elen Landgraf</creatorcontrib><creatorcontrib>da Silva Soares de Souza, Maricelma</creatorcontrib><creatorcontrib>de Souza, Gabriela Achete</creatorcontrib><creatorcontrib>Fidalgo, Thiago Marques</creatorcontrib><creatorcontrib>Araújo, Adriano Cressoni</creatorcontrib><creatorcontrib>de Souza Gonzaga, Heron F</creatorcontrib><creatorcontrib>de Bortoli Teixeira, Daniel</creatorcontrib><creatorcontrib>de Oliveira Silva Ullmann, Thais</creatorcontrib><creatorcontrib>Sloan, Katia Portero</creatorcontrib><creatorcontrib>Sloan, Lance Alan</creatorcontrib><title>GLP-1a: Going beyond Traditional Use</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The objective of this study was to perform a systematic review on the use of GLP-1 other than in treating diabetes. PubMed, Cochrane, and Embase were searched, and the PRISMA guidelines were followed. Nineteen clinical studies were selected. The results showed that GLP-1 agonists can benefit defined off-medication motor scores in Parkinson's Disease and improve emotional well-being. In Alzheimer's disease, GLP-1 analogs can improve the brain's glucose metabolism by improving glucose transport across the blood-brain barrier. In depression, the analogs can improve quality of life and depression scales. GLP-1 analogs can also have a role in treating chemical dependency, inhibiting dopaminergic release in the brain's reward centers, decreasing withdrawal effects and relapses. These medications can also improve lipotoxicity by reducing visceral adiposity and decreasing liver fat deposition, reducing insulin resistance and the development of non-alcoholic fatty liver diseases. The adverse effects are primarily gastrointestinal. Therefore, GLP-1 analogs can benefit other conditions besides traditional diabetes and obesity uses.</description><subject>Adipocytes</subject><subject>Adipose tissue</subject><subject>Agonists</subject><subject>Alzheimer's disease</subject><subject>Analogs</subject><subject>Apoptosis</subject><subject>Appetite</subject><subject>Blood-brain barrier</subject><subject>Body fat</subject><subject>Body mass index</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Disease Management</subject><subject>Dopamine receptors</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>Fatty liver</subject><subject>Gastrointestinal system</subject><subject>Gastrointestinal tract</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucagon-Like Peptide 1 - metabolism</subject><subject>Glucagon-Like Peptide 1 - pharmacology</subject><subject>Glucagon-Like Peptide 1 - therapeutic use</subject><subject>Glucagon-Like Peptide-1 Receptor - agonists</subject><subject>Glucose</subject><subject>Glucose metabolism</subject><subject>Glucose transport</subject><subject>Hepatocytes</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Inhibition (psychology)</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Metabolism</subject><subject>Neurodegenerative Diseases - drug therapy</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Pancreas</subject><subject>Parkinson's disease</subject><subject>Peptide Fragments - metabolism</subject><subject>Peptide Fragments - pharmacology</subject><subject>Peptide Fragments - therapeutic use</subject><subject>Psoriasis</subject><subject>Quality of life</subject><subject>Reinforcement</subject><subject>Review</subject><subject>Systematic review</subject><subject>Treatment Outcome</subject><subject>Weight control</subject><subject>Well being</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkE1Lw0AQhhdRbK3ePEtADx6M7mc260GQolUo6KE9L5vNpG5JszWbCP33praW6mkG5uFl3gehc4JvGVP4zs0XgTJMsWTqAPUJpzTGOJGHe3sPnYQwx5gyKtQx6jGBBVeU99HVaPweE3MfjbyrZlEGK1_l0aQ2uWucr0wZTQOcoqPClAHOtnOAps9Pk-FLPH4bvQ4fx7HlhDaxzSUYRlRS5CJP0wwkzqgVGBiIQiRKFmkiC1aA5Ypxia0QJGUEIKNGqixlA_SwyV222QJyC1VTm1Iva7cw9Up74_TfS-U-9Mx_6VRKwfE64HobUPvPFkKjFy5YKEtTgW-DpgmlVPKufIde_kPnvq27wj8UYTRhfE3dbChb-xBqKHbPEKzX-vW-_g6_2C-wg399s2_F5H6R</recordid><startdate>20220110</startdate><enddate>20220110</enddate><creator>Laurindo, Lucas Fornari</creator><creator>Barbalho, Sandra Maria</creator><creator>Guiguer, Elen Landgraf</creator><creator>da Silva Soares de Souza, Maricelma</creator><creator>de Souza, Gabriela Achete</creator><creator>Fidalgo, Thiago Marques</creator><creator>Araújo, Adriano Cressoni</creator><creator>de Souza Gonzaga, Heron F</creator><creator>de Bortoli Teixeira, Daniel</creator><creator>de Oliveira Silva Ullmann, Thais</creator><creator>Sloan, Katia Portero</creator><creator>Sloan, Lance Alan</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5716-2444</orcidid><orcidid>https://orcid.org/0000-0002-9930-9694</orcidid><orcidid>https://orcid.org/0000-0003-3159-0982</orcidid><orcidid>https://orcid.org/0000-0002-5035-876X</orcidid><orcidid>https://orcid.org/0000-0001-8776-561X</orcidid></search><sort><creationdate>20220110</creationdate><title>GLP-1a: Going beyond Traditional Use</title><author>Laurindo, Lucas Fornari ; Barbalho, Sandra Maria ; Guiguer, Elen Landgraf ; da Silva Soares de Souza, Maricelma ; de Souza, Gabriela Achete ; Fidalgo, Thiago Marques ; Araújo, Adriano Cressoni ; de Souza Gonzaga, Heron F ; de Bortoli Teixeira, Daniel ; de Oliveira Silva Ullmann, Thais ; Sloan, Katia Portero ; Sloan, Lance Alan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-cd7ea3196fd5d88be70b2c50e3e5f5697f867f3fec493470c551831eeb2a79b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adipocytes</topic><topic>Adipose tissue</topic><topic>Agonists</topic><topic>Alzheimer's disease</topic><topic>Analogs</topic><topic>Apoptosis</topic><topic>Appetite</topic><topic>Blood-brain barrier</topic><topic>Body fat</topic><topic>Body mass index</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Disease Management</topic><topic>Dopamine receptors</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>Fatty liver</topic><topic>Gastrointestinal system</topic><topic>Gastrointestinal tract</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucagon-Like Peptide 1 - metabolism</topic><topic>Glucagon-Like Peptide 1 - pharmacology</topic><topic>Glucagon-Like Peptide 1 - therapeutic use</topic><topic>Glucagon-Like Peptide-1 Receptor - agonists</topic><topic>Glucose</topic><topic>Glucose metabolism</topic><topic>Glucose transport</topic><topic>Hepatocytes</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Inhibition (psychology)</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Metabolism</topic><topic>Neurodegenerative Diseases - drug therapy</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Pancreas</topic><topic>Parkinson's disease</topic><topic>Peptide Fragments - metabolism</topic><topic>Peptide Fragments - pharmacology</topic><topic>Peptide Fragments - therapeutic use</topic><topic>Psoriasis</topic><topic>Quality of life</topic><topic>Reinforcement</topic><topic>Review</topic><topic>Systematic review</topic><topic>Treatment Outcome</topic><topic>Weight control</topic><topic>Well being</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laurindo, Lucas Fornari</creatorcontrib><creatorcontrib>Barbalho, Sandra Maria</creatorcontrib><creatorcontrib>Guiguer, Elen Landgraf</creatorcontrib><creatorcontrib>da Silva Soares de Souza, Maricelma</creatorcontrib><creatorcontrib>de Souza, Gabriela Achete</creatorcontrib><creatorcontrib>Fidalgo, Thiago Marques</creatorcontrib><creatorcontrib>Araújo, Adriano Cressoni</creatorcontrib><creatorcontrib>de Souza Gonzaga, Heron F</creatorcontrib><creatorcontrib>de Bortoli Teixeira, Daniel</creatorcontrib><creatorcontrib>de Oliveira Silva Ullmann, Thais</creatorcontrib><creatorcontrib>Sloan, Katia Portero</creatorcontrib><creatorcontrib>Sloan, Lance Alan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laurindo, Lucas Fornari</au><au>Barbalho, Sandra Maria</au><au>Guiguer, Elen Landgraf</au><au>da Silva Soares de Souza, Maricelma</au><au>de Souza, Gabriela Achete</au><au>Fidalgo, Thiago Marques</au><au>Araújo, Adriano Cressoni</au><au>de Souza Gonzaga, Heron F</au><au>de Bortoli Teixeira, Daniel</au><au>de Oliveira Silva Ullmann, Thais</au><au>Sloan, Katia Portero</au><au>Sloan, Lance Alan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GLP-1a: Going beyond Traditional Use</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2022-01-10</date><risdate>2022</risdate><volume>23</volume><issue>2</issue><spage>739</spage><pages>739-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The objective of this study was to perform a systematic review on the use of GLP-1 other than in treating diabetes. PubMed, Cochrane, and Embase were searched, and the PRISMA guidelines were followed. Nineteen clinical studies were selected. The results showed that GLP-1 agonists can benefit defined off-medication motor scores in Parkinson's Disease and improve emotional well-being. In Alzheimer's disease, GLP-1 analogs can improve the brain's glucose metabolism by improving glucose transport across the blood-brain barrier. In depression, the analogs can improve quality of life and depression scales. GLP-1 analogs can also have a role in treating chemical dependency, inhibiting dopaminergic release in the brain's reward centers, decreasing withdrawal effects and relapses. These medications can also improve lipotoxicity by reducing visceral adiposity and decreasing liver fat deposition, reducing insulin resistance and the development of non-alcoholic fatty liver diseases. The adverse effects are primarily gastrointestinal. Therefore, GLP-1 analogs can benefit other conditions besides traditional diabetes and obesity uses.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35054924</pmid><doi>10.3390/ijms23020739</doi><orcidid>https://orcid.org/0000-0002-5716-2444</orcidid><orcidid>https://orcid.org/0000-0002-9930-9694</orcidid><orcidid>https://orcid.org/0000-0003-3159-0982</orcidid><orcidid>https://orcid.org/0000-0002-5035-876X</orcidid><orcidid>https://orcid.org/0000-0001-8776-561X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2022-01, Vol.23 (2), p.739 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8775408 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Adipocytes Adipose tissue Agonists Alzheimer's disease Analogs Apoptosis Appetite Blood-brain barrier Body fat Body mass index Clinical medicine Clinical trials Clinical Trials as Topic Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Disease Management Dopamine receptors Drug dosages Enzymes Fatty liver Gastrointestinal system Gastrointestinal tract GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide 1 - metabolism Glucagon-Like Peptide 1 - pharmacology Glucagon-Like Peptide 1 - therapeutic use Glucagon-Like Peptide-1 Receptor - agonists Glucose Glucose metabolism Glucose transport Hepatocytes Homeostasis Humans Hyperglycemia Inhibition (psychology) Insulin Insulin resistance Liver Liver diseases Metabolism Neurodegenerative Diseases - drug therapy Obesity Obesity - drug therapy Pancreas Parkinson's disease Peptide Fragments - metabolism Peptide Fragments - pharmacology Peptide Fragments - therapeutic use Psoriasis Quality of life Reinforcement Review Systematic review Treatment Outcome Weight control Well being |
| title | GLP-1a: Going beyond Traditional Use |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T18%3A03%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GLP-1a:%20Going%20beyond%20Traditional%20Use&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Laurindo,%20Lucas%20Fornari&rft.date=2022-01-10&rft.volume=23&rft.issue=2&rft.spage=739&rft.pages=739-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms23020739&rft_dat=%3Cproquest_pubme%3E2622274054%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2621326344&rft_id=info:pmid/35054924&rfr_iscdi=true |